WO1998009642A3 - Therapeutic chemokine antagonists - Google Patents

Therapeutic chemokine antagonists Download PDF

Info

Publication number
WO1998009642A3
WO1998009642A3 PCT/US1997/015594 US9715594W WO9809642A3 WO 1998009642 A3 WO1998009642 A3 WO 1998009642A3 US 9715594 W US9715594 W US 9715594W WO 9809642 A3 WO9809642 A3 WO 9809642A3
Authority
WO
WIPO (PCT)
Prior art keywords
chemokine antagonists
therapeutic
polypeptides
cells
therapeutic chemokine
Prior art date
Application number
PCT/US1997/015594
Other languages
French (fr)
Other versions
WO1998009642A9 (en
WO1998009642A2 (en
Inventor
Joost J Oppenheim
Ji Ming Wang
Oleg Y Chertov
Larry O Arthur
Original Assignee
Us Health
Joost J Oppenheim
Ji Ming Wang
Oleg Y Chertov
Larry O Arthur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Joost J Oppenheim, Ji Ming Wang, Oleg Y Chertov, Larry O Arthur filed Critical Us Health
Priority to AU42511/97A priority Critical patent/AU4251197A/en
Publication of WO1998009642A2 publication Critical patent/WO1998009642A2/en
Publication of WO1998009642A3 publication Critical patent/WO1998009642A3/en
Publication of WO1998009642A9 publication Critical patent/WO1998009642A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Polypeptides that bind CD4, including the HIV-1 coat proteins gp120 and gp41, reduce migration of CD4+ cells such as monocytes and T cells in response to chemoattractants, including C-C chemokines, SDF-1α, and fMLP. Such polypeptides are useful for treating inflammatory conditions and diseases.
PCT/US1997/015594 1996-09-06 1997-09-05 Therapeutic chemokine antagonists WO1998009642A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU42511/97A AU4251197A (en) 1996-09-06 1997-09-05 Therapeutic chemokine antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2470896P 1996-09-06 1996-09-06
US60/024,708 1996-09-06

Publications (3)

Publication Number Publication Date
WO1998009642A2 WO1998009642A2 (en) 1998-03-12
WO1998009642A3 true WO1998009642A3 (en) 1998-07-09
WO1998009642A9 WO1998009642A9 (en) 1998-08-13

Family

ID=21821982

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/015594 WO1998009642A2 (en) 1996-09-06 1997-09-05 Therapeutic chemokine antagonists

Country Status (2)

Country Link
AU (1) AU4251197A (en)
WO (1) WO1998009642A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047158A2 (en) * 1998-03-13 1999-09-23 The University Of British Columbia Therapeutic chemokine receptor antagonists
WO2000009152A1 (en) * 1998-08-14 2000-02-24 The University Of British Columbia Therapeutic chemokine receptor antagonists
CA2245224A1 (en) 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
IL138654A0 (en) * 1998-03-25 2001-10-31 Mayo Foundation Methods and materials for treating inflammatory diseases
US6399078B1 (en) 1998-06-01 2002-06-04 University Of Maryland Biotechnology Institute Chemokine—glycosaminoglycan complexes and their use in treating or preventing receptor mediated diseases
WO1999065507A1 (en) * 1998-06-19 1999-12-23 The General Hospital Corporation Modulating platelet function
AU2862300A (en) * 1999-01-29 2000-08-18 Millennium Pharmaceuticals, Inc. Methods for preventing graft rejection and ischemia-reperfusion injury
JP2003502282A (en) 1999-04-08 2003-01-21 ザ ゼネラル ホスピタル コーポレーション Intentional migration of human metastatic cells away from the source of the agent
US7368425B2 (en) 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
US20050059584A1 (en) 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
US7378098B2 (en) 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US9789171B2 (en) 2004-11-05 2017-10-17 The General Hospital Corporation Anti-fugetactic agents for the treatment of ovarian cancer
EP1674077A1 (en) * 2004-12-27 2006-06-28 Université de Liège Mucoadhesive pharmaceutical compositions comprising chemoattractants
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
WO2020106754A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023746A1 (en) * 1993-04-16 1994-10-27 Syntello Vaccine Development Ab Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
WO1994028920A1 (en) * 1993-06-07 1994-12-22 Duke University Synthetic peptide inhibitors of hiv transmission

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023746A1 (en) * 1993-04-16 1994-10-27 Syntello Vaccine Development Ab Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
WO1994028920A1 (en) * 1993-06-07 1994-12-22 Duke University Synthetic peptide inhibitors of hiv transmission

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COCCHI F.: "The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection", NATURE MEDICINE, vol. 2, no. 11, November 1996 (1996-11-01), pages 1244 - 1247, XP002053252 *
DRAGIC T. ET AL.: "HIV-1 entry into CD4+ cells is mediated by chemokine receptor CC-CKR-5", NATURE, vol. 381, no. 6584, 20 June 1996 (1996-06-20), pages 667 - 673, XP002053250 *
HESSELGESSER J ET AL: "CD4 -independent association between HIV-1 gp120 and CXCR4: Functional chemokine receptors are expressed in human neurons.", CURRENT BIOLOGY 7 (2). 1997. 112-121, XP002053251 *
STEFANO G B ET AL: "HIV G120 ALTERATION OF DAMA AND IL-1-ALPHA INDUCED CHEMOTAXIC RESPONSES IN HUMAN AND INVERTEBRATE IMMUNOCYTES.", J NEUROIMMUNOL 43 (1-2). 1993. 177-184, XP002053249 *

Also Published As

Publication number Publication date
AU4251197A (en) 1998-03-26
WO1998009642A2 (en) 1998-03-12

Similar Documents

Publication Publication Date Title
WO1998009642A3 (en) Therapeutic chemokine antagonists
WO1997045543A3 (en) Cc chemokine receptor 5, antibodies thereto, transgenic animals
ATE404583T1 (en) FUNCTIONAL ANTAGONISTS OF HEDGEHOG ACTIVITY
ATE175446T1 (en) IMMUNOGENIC PEPTIDES, ANTIBODIES AND THEIR USES IN CONNECTION WITH CD4 RECEPTOR BINDING
EP1686172A3 (en) Myocardial grafts and cellular compositions useful for same
MX9203439A (en) A MAMMALIAN CYTOKINE, IL-11
NL300139I1 (en) Recombinant pox viruses, immunological compositions comprising a recombinant pox virus and method of expressing the DNA in a recombinant pox virus.
NO973933D0 (en) Vascular endothelial growth factor B
ATE140968T1 (en) CULTURE OF THE VASCULAR ENDOTHELIAL CELL GROWTH FACTOR AND DNA CODING IT
AU4455896A (en) A chemokine receptor able to bind to mcp-1, mip-1 alpha and/or rantes. its uses
IL138424A (en) Covalently reactive antigen analogs and pharmaceutical compositions containing the same
DE69826684D1 (en) COVALENT-TIED N, O-CARBOXYMETHYLCHITOSAN AND ITS USE
WO2000053633A3 (en) Antibody and chemokine constructs that are directed to ccr5, and their use for treating autoimmune diseases
ES2012129A6 (en) Soluble human cd4 fragments and uses therefor.
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
EP0306219A3 (en) Novel hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
AU3526689A (en) Peptides that block the binding of hiv-1 to the cd4 receptor protein
ES2192199T3 (en) LIGANDOS OF THE EPH BIOLOGICALLY ACTIVE FAMILY.
AU6941000A (en) Polypeptides that bind hiv gp120 and related nucleic acids, antibodies, compositions, and methods of use
CA2218372A1 (en) Antagonists of human interleukin-6 that are totally incapable of binding gp 130, and their use in the preparation of pharmaceutical compounds
TR200000140T2 (en) Determination of human cell lines for human protein production by endogenic gene activity
DK1137786T3 (en) Virus coating protein / receptor chimeras and methods for their use
AU687623B2 (en) Cell Adhesion peptides for use in modifying mutual adhesion among eukaryotic cells
AU590861B2 (en) New human lymphotoxin (TNF-beta) polypeptides their prepartion and use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 20 AND 30, DESCRIPTION, REPLACED BY NEW PAGES 20 AND 30; PAGES 1/8-8/8, DRAWINGS, REPLACED BYNEW PAGES 1/8-8/8; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998512906

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA